Clinical Trial Update: Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas [Phase 2]

View source ↗

Summary

This trial update notes the completion of Phase II evaluation of the Gemcitabine–Rituximab–Oxaliplatin (GROC) regimen in relapsed/refractory aggressive non-Hodg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Rituxan (rituximab)

Snippet

Sponsor: Auxilio Mutuo Cancer Center | Conditions: Refractory Aggressive Non-Hodgkin's Lymphoma, Relapsing Aggressive Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED